Skip to content

uPAR PET/MRI in glioma

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519723-20-01
Acronym
2016-002417-21
Enrollment
61
Registered
2025-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Brief summary

Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/MRI scan performed within 1 hour following injection of 68Ga-NOTA-AE105, compared with immunohistochemistry of uPAR (semiquantitative)

Detailed description

The prognostic significance of uPAR expression, as assessed by uPAR-PET/MRI, will be evaluated for its correlation with overall and progression free survival. Patients will be followed for a total of 36 months post uPAR-PET/MRI

Interventions

DRUG[68Ga]NOTA-AE105

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/MRI scan performed within 1 hour following injection of 68Ga-NOTA-AE105, compared with immunohistochemistry of uPAR (semiquantitative)

Secondary

MeasureTime frame
The prognostic significance of uPAR expression, as assessed by uPAR-PET/MRI, will be evaluated for its correlation with overall and progression free survival. Patients will be followed for a total of 36 months post uPAR-PET/MRI

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026